在循环瘤DNA中个性化突变跟踪预测高风险早期乳腺癌患者的复发
Sao Trung Nguyen1, Van-Anh Nguyen Hoang2,3, Vu Nguyen Trieu4
1University of Medicine and Pharmacy, Ho Chi Minh city, Vietnam.
NPJ breast cancer
|June 20, 2025
概括
在手术前后检测循环瘤DNA (ctDNA) 可以预测早期乳腺癌 (BC) 患者的复发风险. 监测ctDNA水平为个性化BC管理和改善无病生存结果提供了宝贵的见解.
科学领域:
- 在瘤学瘤学.
- 分子诊断学 分子诊断学
- 基因组学就是基因组学.
背景情况:
- 循环瘤DNA (ctDNA) 在乳腺癌 (BC) 管理中的临床实用性仍然不完全定义.
- 早期的BC患者需要精确的工具来进行复发风险分层和治疗指导.
研究的目的:
- 为了前性地评估ctDNA在预测疾病复发和早期BC.早期的生存中的作用.
- 评估手术前和手术后ctDNA状态与无病生存期 (DFS) 之间的关联.
主要方法:
- 对168名早期BC患者进行了前性研究,并进行了连续血液样本采集.
- 使用下一代测序和个性化多重PCR (mPCR) 来追踪突变的瘤告知ctDNA分析.
- 在手术前,手术后和监测期间监测ctDNA水平.
主要成果:
- 在手术前的ctDNA阳性显着与DFS降低相关 (HR=3.09,p=0.001).
- 手术后ctDNA检测预测了复发,监测期间的中位数预测时间为9.7个月 (90.9%的灵敏度,98.8%的特异性).
- 手术后ctDNA清除与显著更长的DFS相关 (p=0.0009).
结论:
- 手术前后的ctDNA状态是一个强大的生物标志物,用于在早期BC中分层复发风险.
- 序列ctDNA监测可以帮助早期发现复发,并为辅助治疗决策提供信息.
- ctDNA分析对个性化乳腺癌管理和改善患者治疗结果具有显著的前景.
更多相关视频
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
7.4K
10:35A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction
Published on: April 5, 2018
10.5K
相关概念视频
02:50Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
02:21Cancers Originate from Somatic Mutations in a Single Cell
13.1K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
13.1K